Paula Greter: Access and Innovation in Hemophilia through ERAH2026
Paula Greter, Commercial Strategy and Market Access Director at Roche Brazil, shared a post on LinkedIn:
”Participating in ERAH2026 truly reinforced what drives me at Roche Farma Brasil: our purpose to transform science into hope and meaningful quality of life for families.
This is an unyielding pursuit of solutions that challenge the impossible.
In our long-term journey with the community, hemophilia remains a core priority, keeping us dedicated to securing two essential pillars: access and innovation.
To drive the future forward , we continually invest in developing next-generation approaches.
Alongside this, we take great pride in our humanitarian aid program in partnership with the WFH, bringing access to communities in over 30 countries.
Our commitment is continuous: ensuring that these patients’ lives keep moving forward, always.
Let’s keep this momentum alive.”
Stay updated with Hemostasis Today.
-
May 22, 2026, 17:30Veronica Sanchez: Do You Live with Pain after a Stroke?
-
May 22, 2026, 17:25Maxime Dely: A Simple but Powerful Indicator of Platelet Quality
-
May 22, 2026, 17:24Jim Hoffman: A New Approach to Balancing Host Defense and Tissue Protection
-
May 22, 2026, 17:22Lucia Rugeri: Advancing Multidisciplinary Care for Heavy Menstrual Bleeding in Women with Bleeding Disorders
-
May 22, 2026, 17:20Nour Al-Mozain: Optimizing PBSC Collection Through Real-Time CD34+ Monitoring
-
May 22, 2026, 16:30Buse Bor: New Publication on Therapeutic Interventions for Women with Obstetric APS
-
May 22, 2026, 16:29Danny Hsu: The Reversal Dilemma – Rethinking our approach to DOAC-associated ICH
-
May 22, 2026, 16:28Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance
-
May 22, 2026, 16:26Sandeep De: Omicron COVID Infections Linked to Coronary Thrombosis without Detectable Plaque